Citations

Showing 10 of 108119 citations.

A Mixed-Methods Exploration of Pediatric Intensivists' Attitudes toward End-of-Life Care in Vietnam
Fadadu, Priyal , Liu, Joy C., Schiltz, Brenda , Xoay, Tran Dang , Phúc, Phan Hữu , Kumbamu, Ashok , Ouellette, Yves , Fadadu, Priyal P, Schiltz, Brenda M, Fadadu, Priyal P

Mayo Clinic

Journal of Palliative Medicine | February 6, 2019 | Volume: 22 | Issue: 8 | Pages: 885-893

10.1089/jpm.2018.0496 | PMID 30724688 Get It

Abstract Background: Although the need for palliative care is gaining recognition in Southeast Asia, knowledge about how decisions are made for children near the end of life remains sparse. Objective: To explore pediatric intensivists' attitudes and practices surrounding end-of-life care in Vietnam. Methods: This is a mixed-methods study conducted at a tertiary pediatric and neonatal intensive care unit in Hanoi. Physicians and nurses completed a quantitative survey about their views on end-of-life care. A subset of these providers participated in semistructured interviews on related topics. Analysis of surveys and interviews were conducted. Results were triangulated. Results: Sixty-eight providers (33 physicians and 35 nurses) completed the quantitative survey, and 18 participated in interviews. Qualitative data revealed three overarching themes with numerous subthemes and supporting quotations. The first theme was factors influencing providers' decision-making process to escalate or withdraw treatment. Quantitative data showed that 40% of providers valued the family's ability to pay to continue life-sustaining treatment. Second, communication dynamics in decision making were highlighted; 72% of providers would be willing to override a family's wishes to withdraw life-sustaining treatment. Third, provider perceptions of death varied, with 68% regarding their patients' deaths as a personal failure. Conclusions: We elicited and documented how pediatric intensivists in Vietnam currently think about and provide end-of-life care. These findings indicate a need to strengthen palliative care training, increase family involvement in decision making, implement standardized and official do-not-resuscitate documentation, and expand pediatric hospice services at the individual, hospital, and national levels in Vietnam.
Public perceptions of changing the terminology for low-risk thyroid cancer: a qualitative focus group study
Nickel, Brooke , Semsarian, C. , Moynihan, Ray , Barratt, Alexandra , Jordan, Susan J. , McLeod, Donald S.A. , Brito, Juan P. , McCaffery, Kirsten , Brito, Juan P

Mayo Clinic

BMJ Open | February 6, 2019 | Volume: 9 | Issue: 2 | Pages: e025820

10.1136/bmjopen-2018-025820 | PMID 30813118 Get It

Objectives To investigate public perceptions of overdiagnosis and overtreatment in low-risk thyroid cancer and explore opinions regarding the proposed strategy to change the terminology of low-risk cancers. Design Qualitative study using focus groups that included a guided group discussion and presentation explaining thyroid cancer, overdiagnosis and overtreatment, and proposed communication strategies. Transcripts were analysed thematically. Setting Sydney, Australia. Participants Forty-seven men and women of various ages from a range of socioeconomic backgrounds with no personal history of thyroid cancer. Results Participants had low pre-existing general awareness of concepts of overdiagnosis and overtreatment and expressed concern regarding this new information in relation to thyroid cancer. Overall, participants understood why the strategy to change the terminology was being proposed and could see potential benefits including reducing the negative psychological impact and stigma associated with the term ‘cancer’; however, many still had reservations about the strategy. The majority of the concerns were around their worry about the risk of further disease progression and that changing the terminology may create confusion and cause patients not to take the diagnosis and its associated managements seriously. Despite varied views towards the proposed strategy, there was a strong overarching desire for greater patient and public education around overdiagnosis and overtreatment in both thyroid cancer and cancer generally in order to complement any revised terminology and/or other mitigation strategies. Conclusions We found a strong and apparently widely held desire for more information surrounding the topic of overdiagnosis and overtreatment. Careful consideration of how to inform both the public and current patients about the implications of a change in terminology, including changes to patients’ follow-up or treatments, would be needed if such a change were to go ahead.
The skeletal impact of cancer therapies
Bedatsova, Lucia, Drake, Matthew T. , Drake, Matthew T

Mayo Clinic

British Journal of Clinical Pharmacology | February 6, 2019 | Volume: 85 | Issue: 6 | Pages: 1161-1168

10.1111/bcp.13866 | PMID 30723928 Get It

AbstractBoth cancer and therapies used in the treatment of cancer can have significant deleterious effects on the skeleton, increasing the risks for both bone loss and fracture development. While advancements in cancer therapies have resulted in enhanced cancer survivorship for patients with many types of malignancies, it is increasingly recognized that efforts to reduce bone loss and limit fractures must be considered for nearly all patients undergoing cancer therapy in order to diminish the anticipated future skeletal consequences. To date, most studies examining the impact of cancer therapies on skeletal outcomes have focused on endocrine‐associated cancers of the breast and prostate, with more recent advances in our understanding of bone loss and fracture risk in other malignancies. Pharmacologic efforts to limit the adverse effects of cancer therapies on bone have nearly universally employed anti‐resorptive approaches, although studies have frequently relied on surrogate outcomes such as changes in bone mineral density or bone turnover markers, rather than on fractures or other skeletal‐related events, as primary study endpoints. Compounding current deficiencies for the provision of optimal care is the recognition that despite clearly written and straightforward society‐based guidelines, vulnerable eligible patients are very often neither identified nor provided with appropriate treatments to limit the skeletal impact of their cancer therapies.
Heterogeneous Immunoassay Using Channels and Droplets in a Digital Microfluidic Platform
Liu, Yuguang , Papautsky, Ian

Mayo Clinic

Micromachines | February 6, 2019 | Volume: 10 | Issue: 2 | Pages: 107

10.3390/mi10020107 | PMID 30764575 Get It

This work presents a heterogeneous immunoassay using the integrated functionalities of a channel and droplets in a digital microfluidic (DMF) platform. Droplet functionality in DMF allows for the programmable manipulation of discrete sample and reagent droplets in the range of nanoliters. Pressure-driven channels become advantageous over droplets when sample must be washed, as the supernatant can be thoroughly removed in a convenient and rapid manner while the sample is immobilized. Herein, we demonstrate a magnetic bead-based, enzyme-linked immunosorbent assay (ELISA) using ~60 nL of human interleukin-6 (IL-6) sample. The wash buffer was introduced in the form of a wall-less virtual electrowetting channel by a syringe pump at the flow rate of 10 μL/min with ~100% bead retention rate. Critical parameters such as sample wash flow rate and bead retention rate were optimized for reliable assay results. A colorimetric readout was analyzed in the International Commission on Illumination (CIE) color space without the need for costly equipment. The concepts presented in this work are potentially applicable in rapid neonatal disease screening using a finger prick blood sample in a DMF platform.
Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience
O’Leary, Jacqueline G. , Bajaj, Jasmohan S. , Biggins, Scott W. , Wong, Florence , Kamath, Patrick S. , García‐Tsao, Guadalupe , Maliakkal, Benedict, Lai, Jennifer C. , Fallon, Michael B. , Vargas, Hugo E. , Thuluvath, Paul J. , Subramanian, Ram, Reddy, K. Rajender , Wong, Florence , Lai, Jennifer , Rajender Reddy, K , Vargas, Hugo E , Tandon, Puneeta , García–Tsao, Guadalupe , Thacker, Leroy R.

Mayo Clinic

Liver Transplantation | February 6, 2019 | Volume: 25 | Issue: 4 | Pages: 571-579

10.1002/lt.25426 | PMID 30724010 Get It

Acute‐on‐chronic liver failure (ACLF) characterized with ≥2 extrahepatic organ failures in cirrhosis carries a high mortality. Outcomes of patients listed for liver transplantation (LT) after ACLF and after LT are largely unknown. The North American Consortium for the Study of End‐Stage Liver Disease prospectively enrolled 2793 nonelectively hospitalized patients with cirrhosis; 768 were listed for LT. Within 3 months, 265 (35%) received a LT, 395 remained alive without LT, and 108 died/delisted. Compared with nonlisted patients, those listed were younger and more often had ACLF, acute kidney injury, and a higher admission Model for End‐Stage Liver Disease (MELD) score. ACLF was most common in patients who died/delisted, followed by those alive with and without LT respectively, (30%, 22%, and 7%, respectively; P < 0.001). At LT, median MELD was 27.9% and 70% were inpatients; median time from hospitalization to LT was 26 days. Post‐LT survival at 6 months was unchanged between those with and without ACLF (93% each at 6 months). There was no difference in 3‐ and 6‐month mean post‐LT creatinine in those with and without ACLF, despite those with ACLF having a higher mean pre‐LT creatinine and a higher rate of perioperative dialysis (61%). In conclusion, patients with and without ACLF had similar survival after transplant with excellent renal recovery in both groups.
Autoimmune glial fibrillary acidic protein astrocytopathy
Kunchok, Amy , Ζεκερίδου, Αναστασία , McKeon, Andrew , Zekeridou, Anastasia, Pittock, Sean J , McKeon, Andrew

Mayo Clinic

Current Opinion in Neurology | February 6, 2019 | Volume: 32 | Issue: 3 | Pages: 452-458

10.1097/wco.0000000000000676 | PMID 30724768 Get It

Purpose of review To describe a recently characterized autoimmune, inflammatory central nervous system (CNS) disorder known as autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy. Recent findings Affected patients present with symptoms of one or more of meningitis (headache and neck ache), encephalitis (delirium, tremor, seizures, or psychiatric symptoms), and myelitis (sensory symptoms and weakness). Optic disc papillitis (blurred vision) is common. CNS inflammation is evident in characteristic T1 postgadolinium enhancement of GFAP-enriched CNS regions, and lymphocytic cerebrospinal fluid (CSF) white cell count elevation. CSF is more reliable than serum for GFAP-immunoglobulin G (IgG) testing. Ovarian teratoma commonly coexists, particularly among patients with accompanying N-methyl-D-aspartate receptor or aquaporin-4 autoimmunity. Parainfectious autoimmunity is suspected in some other patients, though the culprit organism is rarely verified. Pathophysiologic relevance of T cells is underscored by neuropathology and cases of dysregulated T-cell function (HIV or checkpoint inhibitor cancer therapy). Corticosteroid-responsiveness is a hallmark of the disease. Relapses occur in approximately 20% of patients, necessitating transition to a steroid-sparing drug. Reported outcomes vary, though in the authors’ experience, early and sustained intervention usually portends recovery. Summary Autoimmune GFAP astrocytopathy is a treatable autoimmune CNS disease diagnosable by GFAP-IgG testing in CSF. This disease presents opportunities to explore novel mechanisms of CNS autoimmunity and inflammation.
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Bartlett, Nancy L. , Smith, Sonali M. , Leonard, John P. , Evens, Andrew M. , Friedberg, Jonathan W. , Bartlett, Nancy L , Evens, Andrew M , Hsi, Eric D. , Li, Hongli , Nixon, Andrew B. , Schöder, Heiko , LeBlanc, Michael , Kahl, Brad S. , Scott, David W. , Rimsza, Lisa M.

Mayo Clinic

Blood | February 6, 2019 | Volume: 133 | Issue: 16 | Pages: 1762-1765

10.1182/blood-2018-08-870915 | PMID 30723079 Get It

Abstract Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)–positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.
Automated three-dimensional measurements of version, inclination, and subluxation
Shukla, Dave R. , McLaughlin, Richard J. , Lee, Julia , Nguyen, Ngoc Tram V. , Sanchez-Sotelo, Joaquin, Sánchez‐Sotelo, Joaquín , Shukla, Dave R.

Mayo Clinic

Shoulder & Elbow | February 6, 2019 | Volume: 12 | Issue: 1 | Pages: 31-37

10.1177/1758573218825480 | PMID 32010231 Get It

Background Preoperative planning software has been developed to measure glenoid version, glenoid inclination, and humeral head subluxation on computed tomography (CT) for shoulder arthroplasty. However, most studies analyzing the effect of glenoid positioning on outcome were done prior to the introduction of planning software. Thus, measurements obtained from the software can only be extrapolated to predict failure provided they are similar to classic measurements. The purpose of this study was to compare measurements obtained using classic manual measuring techniques and measurements generated from automated image analysis software. Methods Ninety-five two-dimensional computed tomography scans of shoulders with primary glenohumeral osteoarthritis were measured for version according to Friedman method, inclination according to Maurer method, and subluxation according to Walch method. DICOM files were loaded into an image analysis software (Blueprint, Wright Medical) and the output was compared with values obtained manually using a paired sample t-test. Results Average manual measurements included 13.8° version, 13.2° inclination, and 56.2% subluxation. Average image analysis software values included 17.4° version (3.5° difference, p < 0.0001), 9.2° inclination (3.9° difference, p < 0.001), and 74.2% for subluxation (18% difference, p < 0.0001). Conclusions Glenoid version and inclination values from the software and manual measurement on two-dimensional computed tomography were relatively similar, within approximately 4°. However, subluxation measurements differed by approximately 20%.
Team Approach: Management of Scapholunate Instability
Kamal, Robin N. , Moore, Wendy C. , Kakar, Sanjeev , Moore, Wendy , Kakar, Sanjeev , Kamal, Robin N

Mayo Clinic

JBJS Reviews | February 5, 2019 | Volume: 7 | Issue: 2 | Pages: e2-e2

10.2106/jbjs.rvw.18.00021 | PMID 30724763 Get It

* The wrist maintains stability through complex articulations of the carpal bones, dependent upon intrinsic and extrinsic ligaments. * Injury to the scapholunate interosseous ligament may lead to dissociative carpal instability, abnormal carpal kinetics, and sometimes arthritis. * The kinematics, kinetics, and self-stabilizing role of the tendons and their influence on the scapholunate interosseous ligament continue to be studied. * Critical to successful treatment of scapholunate interosseous ligament injuries is timely and complementary therapy. * There is currently no gold standard for a treatment algorithm for this condition.
Treatment of RecurrentClostridium difficileInfection—Reply
Khanna, Sahil , Cifu, Adam S. , Gupta, Arjun

Mayo Clinic

JAMA | February 5, 2019 | Volume: 321 | Issue: 5 | Pages: 513

10.1001/jama.2018.19004 | PMID 30721291 Get It